Last reviewed · How we verify
LAS106521
LAS106521 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.
LAS106521 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels. Used for Atopic dermatitis, Psoriasis.
At a glance
| Generic name | LAS106521 |
|---|---|
| Sponsor | Almirall, S.A. |
| Drug class | Phosphodiesterase 4 (PDE4) inhibitor |
| Target | PDE4 |
| Modality | Small molecule |
| Therapeutic area | Immunology / Dermatology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting PDE4, the drug prevents the breakdown of cyclic adenosine monophosphate (cAMP), leading to elevated intracellular cAMP levels in immune and inflammatory cells. This suppresses the production of pro-inflammatory cytokines and chemokines, reducing inflammation. The mechanism is designed to provide anti-inflammatory effects with potentially improved tolerability compared to earlier PDE4 inhibitors.
Approved indications
- Atopic dermatitis
- Psoriasis
Common side effects
- Nausea
- Diarrhea
- Headache
- Vomiting
Key clinical trials
- Study on the Efficacy of LAS41005 in the Treatment of Actinic Keratosis (PHASE3)
- Efficacy and Safety Study of LAS41007 in the Treatment of Actinic Keratosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LAS106521 CI brief — competitive landscape report
- LAS106521 updates RSS · CI watch RSS
- Almirall, S.A. portfolio CI